Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation.

Zhu Zhu, Zhu Shen, Aiming Shi, Cunjin Su, Jiaojiao Mao, Hong Tao, Feng Xu, Zhanhong Hu, Jie Pan

Heart and vessels 2022 May

filter terms:

This study aimed to evaluate the variability of dabigatran plasma concentration and the association with clinical events in Chinese patients treated with dabigatran etexilate (DE) for non-valvular atrial fibrillation (NVAF). The steady-state concentration of dabigatran (the active metabolite of DE) was determined at trough and peak. The effect of dabigatran concentration variability and related factors on clinical outcomes were explored. Data from 86 patients receiving a fixed dose of 110 mg showed that dabigatran trough concentration varied remarkably. Age, BMI and history of heart failure were identified as important covariates for dabigatran trough concentration. Dabigatran trough concentration (P = 0.002) and history of hypertension (P = 0.012) scores were identified as key factors for predicting the risk of bleeding events. Dabigatran trough concentration, affected by Age, BMI and history of heart failure, may serve as an independent risk factor for bleeding events in Chinese patients treated with DE for NVAF. © 2021. Springer Japan KK, part of Springer Nature.

Citation

Zhu Zhu, Zhu Shen, Aiming Shi, Cunjin Su, Jiaojiao Mao, Hong Tao, Feng Xu, Zhanhong Hu, Jie Pan. Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation. Heart and vessels. 2022 May;37(5):821-827